Skip to main content

Table 1 Clinical, laboratory and diagnostic investigations of patients who received <14 days and ≥ 14 days of acyclovir therapy

From: Should a hospitalized child receive empiric treatment with acyclovir?

  <14 days (n=259) ≥14 days (n=30) Odds ratio (95% CI) p value
Clinical variables, history     
Age (years), median (range) 3.8 (0.01-18) 6.8 (0.07 – 16.7)   0.2
Sex (male), n (%) 152 (59) 13 (43) 0.5 (0.2 – 1.2) 0.1
History of fever, n (%) 171 (66) 19 (63) 0.9 (0.4-2.0) 0.8
History of seizure, n (%) 120 (46) 13 (43) 0.9 (0.4-1.9) 0.8
History of headache, n (%) 70 (27) 9 (30) 1.1 (0.5-2.6) 0.7
History of mucocutaneous HSV, n (%) 3 (0.8) 3 (10) 14.3 (2.3 – 89) <0.01*
Clinical variables, physical examination     
Fever (≥38 C), n (%) 95 (37) 12 (40) 1.2 (0.5 – 2.5) 0.7
Glasgow Coma Scale ≤ 13, n (%) 80 (32) 16 (53) 2.5 (1.2-5.3) 0.02*
Focal neurologic findings, n (%) 30 (12) 11 (37) 4.4 (1.9-10.2) 0.001*
Seizure in ED, n (%) 38 (15) 5 (17) 1.2 (0.4 – 3.2) 0.7
Initial laboratory measures     
WBC, mean (±SD) 13.1 (7.9) 12.7 (6.3)   0.8
CSF corrected WBC, median (range) 4 (0-838) 16 (0-650)   0.05*
CSF protein, median (range) 0.3 (0.1-830) 0.4 (0.1-44)   0.8
Diagnostic investigations     
CT head abnormal, n/N completed (%) 33/194 (17) 7/17 (41) 3.4 (1.2-9.6) 0.03*
MRI head abnormal, n/N completed (%) 46/98 (47) 17/24 (71) 2.7 (1.0-7.2) 0.04*
EEG abnormal, n/N completed (%) 52/128 (41) 16/22 (73) 3.9 (1.4-10.6) 0.005*